SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Equities
6990
CNE1000062J1
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 189 HKD | +6.48% |
|
+12.63% | +83.67% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, formerly Sichuan Kelun Biotech Biopharmaceutical Co Ltd, is a China-based company mainly engaged in the research and development, production, and sales of drugs. The Company is mainly engaged in the research and development, production, and sales of biopharmaceuticals, chemical raw materials, and chemical drug formulations. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
189
HKD
Average target price
184
HKD
Spread / Average Target
-2.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +83.67% | 5.3B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- 6990 Stock
- News Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Kelun-Biotech Shrinks Loss by 7% in 2023
